Lexicon Pharmaceuticals(DE:LX31)
€1.010.00 (0.00%)
DE:LX31
Lexicon Pharmaceuticals stock drug pipeline
€1.01
At close:0.00 (0.00%)
Lexicon Pharmaceuticals (LX31) Drug Pipeline
5 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sotagliflozin | Obstructive Cardiomyopathy, Hypertrophic, Non-Obstructive Hypertrophic Cardiomyopathy | Phase III | Recruiting | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Jun 25, 2024 | ― |
| Lx9211 (Blinded) | Diabetic Peripheral Neuropathic Pain | Phase II | Completed | A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) | Nov 30, 2023 | ― |
| Lx9211 | Postherpetic Neuralgia | Phase II | Completed | Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia | Dec 04, 2020 | ― |
| Lx9211 | Diabetes, Diabetic Peripheral Neuropathy | Phase II | Completed | Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain | Jun 29, 2020 | ― |
| Sotagliflozin | Type 2 Diabetes Mellitus, Heart Failure | Phase III | Terminated | Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) | Apr 30, 2018 | ― |
| Sotagliflozin | Type 2 Diabetes Mellitus | Phase III | Terminated | Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | Dec 21, 2017 | ― |
| Sotagliflozin, Empagliflozin | Type 2 Diabetes Mellitus | Phase III | Completed | Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin | Nov 20, 2017 | ― |
| Metformin, Glimepiride, Sotagliflozin (Sar439954) | Type 2 Diabetes Mellitus | Phase III | Completed | Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy | Nov 02, 2017 | ― |
| Telotristat Ethyl | Hepatic Impairment | Phase I | Completed | Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment | Oct 24, 2017 | ― |
| Sotagliflozin | Type 2 Diabetes Mellitus, Heart Failure, Chronic Kidney Diseases | Phase III | Terminated | Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk | Oct 16, 2017 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sotagliflozin | Phase III | Obstructive Cardiomyopathy, Hypertrophic, Non-Obstructive Hypertrophic Cardiomyopathy | Recruiting | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Jun 25, 2024 | ― |
| Lx9211 (Blinded) | Phase II | Diabetic Peripheral Neuropathic Pain | Completed | A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) | Nov 30, 2023 | ― |
| Lx9211 | Phase II | Postherpetic Neuralgia | Completed | Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia | Dec 04, 2020 | ― |
| Lx9211 | Phase II | Diabetes, Diabetic Peripheral Neuropathy | Completed | Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain | Jun 29, 2020 | ― |
| Sotagliflozin | Phase III | Type 2 Diabetes Mellitus, Heart Failure | Terminated | Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) | Apr 30, 2018 | ― |
| Sotagliflozin | Phase III | Type 2 Diabetes Mellitus | Terminated | Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | Dec 21, 2017 | ― |
| Sotagliflozin, Empagliflozin | Phase III | Type 2 Diabetes Mellitus | Completed | Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin | Nov 20, 2017 | ― |
| Metformin, Glimepiride, Sotagliflozin (Sar439954) | Phase III | Type 2 Diabetes Mellitus | Completed | Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy | Nov 02, 2017 | ― |
| Telotristat Ethyl | Phase I | Hepatic Impairment | Completed | Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment | Oct 24, 2017 | ― |
| Sotagliflozin | Phase III | Type 2 Diabetes Mellitus, Heart Failure, Chronic Kidney Diseases | Terminated | Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk | Oct 16, 2017 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Lexicon Pharmaceuticals (DE:LX31) have in its pipeline
Lexicon Pharmaceuticals DE:LX31 is currently developing the following drugs: Sotagliflozin, Lx9211 (Blinded), Lx9211, Sotagliflozin, Empagliflozin, Metformin, Glimepiride, Sotagliflozin (Sar439954), Telotristat Ethyl, Omeprazole 40 Mg, Famotidine 40 Mg, Telotristat Ethyl 250 Mg, Sotagliflozin, Insulin Glargine (Hoe901), Oral Antidiabetes Drugs (Oads), Metformin, Sulfonylurea, Sotagliflozin (Sar439954), Metformin, Sotagliflozin (Sar439954), Sotagliflozin (Sar439954), Sotagliflozin, Oral Contraceptive, Oral Contraceptive + Sotagliflozin, Lx4211, Telotristat Etiprate, Octreotide Acetate, Telotristat Etiprate, Telotristat Etiprate, Octreotide Lar Depot. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

